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Background: The Italian Ministry of Health decided to introduce community professional services in 2010. This trial
provides an opportunity to evaluate the outcomes of a new professional pharmacy service: Italian Medicines Use
Review (I-MUR) aimed at reducing the severity of asthma and its associated costs.
Methods/Design: This is a cluster randomised controlled trial of the I-MUR service. Data will be collected over time
before, during and after pharmacists’ intervention. Fifteen Italian regions will be involved and it is aimed to recruit
360 community pharmacists and 1800 patients. Each pharmacist will receive training in medicines use review,
recruit five patients, administer the Asthma Control Test and provide the I-MUR service. Pharmacists will be allocated
to different groups, one group will be trained in and provide the I-MUR service immediately after completion of the
baseline ACT score, the other group will receive training in the I-MUR and provide this service three months later.
Group allocation will be random, after stratification by region of Italy. The I-MUR service will involve gathering data
following each patient consultation including demographic details, patients regular medications, including those
used for asthma, their attitude towards their medications and self-reported adherence to treatments. In addition,
pharmacists will identify and record pharmaceutical care issues and any advice given to patients during the I-MUR,
or recommendations given to doctors. Pharmacists will upload trial data onto a web platform for analysis. The
primary outcome measure is the severity of asthma before, during and after the I-MUR assessed using the Asthma
Control Test score. Secondary measures: number of all active ingredients used by patients during and after the
I-MUR, number of pharmaceutical care issues identified during the I-MUR, patients’ self-reported adherence to
asthma medication during and after the I-MUR, healthcare costs based on the severity of asthma, before, during
and after the I-MUR service provision.
Discussion: This study has been developed because of the need for a new way of working for pharmacists and
pharmacies; it is the first trial of any community pharmacy-based pharmaceutical care intervention in Italy. The
results will inform future policy and practice in Italian community pharmacy.
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What is the problem to be addressed?
It is estimated that around 300 million people in the
world have asthma with an additional 100 million cases
predicted by 2025 [1]. The number of disability-adjusted
life years (DALYs) lost to asthma worldwide has been
estimated to be around 15 million per year with an esti-
mated one in every 250 deaths worldwide caused by
asthma [1].
Prevalence of asthma in the European adult popula-
tion, age 18–44, varies from country to country, with the
highest value in Sweden (20.62%) and the lowest in
Bulgaria and Lithuania (2%); in Italy it is 6.2% [2].
The total cost of respiratory diseases in the 28 coun-
tries of the EU alone amounts to more than €380 billion
annually with asthma accounting for €33.9 billion [3].
The total bill includes the costs of direct primary and
hospital healthcare (around €55 billion), the cost of loss
of production (nearly €42 billion) and the monetized
DALYs lost (at least €280 billion).
Overall cost of asthma, including individual direct
costs, indirect costs and intangible quality of life costs
have been related to severity of asthma [4-6].
In 2000, a COI (Cost of Illness) study was carried out
in Italy in the frame of the Italian Study on Asthma in
Young Adults. The mean annual costs for an asthmatic
patient was €741 (95% CI: 599–884) ranging from €379
(95% CI: 216–541) for well-controlled asthmatics to
€1,341 (95% CI: 978–1,706) for poorly controlled cases
that accounted for 46.2% of the total cost [7].
Pharmacists’ role in asthma management
Pharmacists have the potential to improve asthma seve-
rity through interventions, which include counseling on
inhaler technique, medicine therapy management and
medicines use review (MUR) [8-12].
A portrait of the pharmacy profession around the
world suggests a wide variation in the practice of phar-
macy, not only between countries but also within coun-
tries [13].
In England, the Isle of Wight Respiratory project, in-
volved health care practitioners including community
pharmacists. The aim was to reduce respiratory death,
hospital admission and the cost of respiratory medica-
tion. In this study, general practitioners referred patients
to their community pharmacist for inhaler technique
training. The results showed that reliever therapy costs
dropped by 22.7%, emergency admissions due to asthma
reduced by 50%, deaths fell by 75% and hospital in-
patient costs fell by 66%. A review on the NICE shared
database highlighted that the training of health care
practitioners carried a cost, which was paid back seven
times over with the reduction in cost of bronchodilators
within one year of the project [14].In Denmark, a prospective controlled multicenter study,
aimed to improve asthma severity (status) by increasing
the participation of pharmacists and promoting coope-
ration with patients and the patient’s general practitioner
(GP). The study recruited 500 asthmatic patients from pri-
mary care, and found improvements in asthma symptoms
status, quality of life and days of sickness [15].
In Finland, a 10-year asthma program was undertaken
from 1994 to 2004 to improve asthma care and prevent
asthma costs increasing, using general practitioners,
nurses, and pharmacists. The main goal of this program
was to lessen the burden of asthma to individual and to
society. Pharmacists provided patients with written or
oral information on preventers and relievers during 98%
of asthma medication purchases, plus gave instruction
on inhalation technique to 98% of newly diagnosed asth-
matic patients and 34% of patients with existing disease.
Pharmacists’ intervention combined with the ones pro-
vided by GPs and nurses contributed to reduce the num-
ber of days patients were in hospital which fell by 54%;
the increasing cost of asthma had stopped and the
annual cost per patient decreased by 36% from €1,611 to
€1,031 [16].
An Australian multi-site randomised controlled trial
compared pharmacist counseling on asthma, asthma
medication and associated lifestyle advice with a control
group providing usual care. Fifty pharmacies were en-
rolled and randomly allocated to one of the two groups
(randomisation conducted at pharmacy level), the inter-
vention group with 191 patients and the control group
with 205 patients. In both groups questionnaires and
spirometric testing were carried out at baseline and at
six months. The main outcome measure was asthma
severity/control status assessed by a tool adapted from
the National Asthma Council. The percentage of pa-
tients in the intervention group classified as having se-
vere asthma declined from 87.9% to 52.7% (p < 0.01),
whilst the change in the control group the change was
not significant (71.2% to 67.9%; p = 0.11). These authors
used a multilevel logistic regression model to adjust for
the difference in asthma severity at baseline and to
account for any possible effect from clustering. Both
pharmacist groups administered questionnaires and spiro-
metric testing at baseline and six months later; it was
found that patients in the intervention group were almost
three times more likely to change from the severe asthma
category to the not severe category than patients in the
control group (OR 2.68, 95% CI 1.64 to 4.37 p < 0.01) [17].
Medicines use reviews in asthma
The Medicines Use Review (MUR) service was first in-
troduced in England in 2005 as an advanced service in
the community pharmacy contractual framework. The
aim of the MUR is to achieve a concordant consultation
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use, understanding and experience of taking their medi-
cines, with the ultimate aim of improving the clinical
and cost-effectiveness of prescribed medicines, reducing
medicines wastage and improving patient outcomes
through improved adherence [18].
Portlock et al. [19] conducted a study in England in
which 965 MURs were undertaken in patients with asthma.
Pharmacists identified that 37% of the patient popula-
tion were primarily non-adherent (i.e. collected < 75% of
intended asthma prescriptions in the previous 12 months)
and a further 31% had secondary adherence issues (i.e. not
taking their medications in the way they had been in-
tended). Pharmacists made 1,787 interventions (mean 1.8
per MUR consultation) of which 41% were device checks,
10% were referral to a GP or nurse and 49% were
educational.
Another study involving 154 patients with asthma re-
ceiving an MUR found that the proportion of patients
whose asthma was not controlled fell from 59% to 45%
(p < 0.01), 30% of patients were referred to their GPs or
asthma nurse as a result of their MUR and, of those re-
ferred, 70% had a treatment or dosage change [20].
Italian medicines use review (I-MUR)
This study is about developing a similar service in Italy
where no such services exist. The I-MUR has been de-
signed as a structured interview, supported by a quanti-
tative questionnaire enabling pharmacists to capture in a
systematic way a patient’s demographic data, quantity
and type of medicines used, their knowledge about the
medicines used, their adherence to the medicines, actual
complaints (e.g. shortness of breath, chest tightness,
night time waking, need for rescue medicines, limitation
on activity including exercise), plus any pharmaceutical
care issues identified by the pharmacists, the advice
given to physicians and to patients, including healthy
living advice, using an online platform (Qualtrics®).
The Italian government is considering introducing the
I-MUR service, but at present there is no evidence from
Italy on the feasibility, acceptability or effectiveness of
such a model. Hence there is a need to gather robust
data on all aspects of the potential new service to inform
service design and delivery.
A pilot study was carried out between October 2012
and January 2013, to assess the feasibility of Italian com-
munity pharmacists delivering I-MURs to patients with
asthma [21]. In this phase, the MUR template used in
England was adapted and supplemented with a struc-
tured interview to be conducted with patients. The tem-
plate also included the classification of pharmaceutical
care issues (PCIs) which were potentially identifiable by
pharmacists during the patient consultation. Pharma-
ceutical care issues were classified using the methoddeveloped by Krska et al. [22] where they are defined as
“an element of a pharmaceutical need which is addressed
by pharmacists”. This enabled pharmacists to categorize,
using a systematic approach, all issues they found during
the consultation.
This pilot study was carried out in four Italian regions
and involved 74 pharmacists who provided the I-MUR to
895 patients during a four-month period, following trai-
ning [23]. The training provided was evaluated and phar-
macists’ views on the service provision sought through
focus groups. Poor adherence was found in 45% of the
895 patients and only 18% had either no asthma-related
problems – either actual complaints or medicine-related
problems. Pharmacists identified pharmaceutical care is-
sues in 60% of patients; they provided 1008 items of
medicine-related advice to GPs and 1321 to patients, plus
1219 items of healthy living advice. Pharmacists’ clinical
knowledge increased by 24%; following training and
I-MUR service provision.
Following this pilot study, which focused on pharma-
cists, a second study, conducted between October and
November 2013, sought to obtain patients’ feedback and
GPs’ views on the I-MUR service provision. All patients
who had received the I-MUR service previously were in-
vited to complete a feedback questionnaire. Responses
were obtained from 246 patients (27% response rate).
The questionnaire found that 50% of patients were nei-
ther worried nor had problems with their medicines be-
fore having the I-MUR, but 75% of them confirmed that
they benefited from the service. Seventy-five percent of
patients also indicated they felt involved in all the dis-
cussion, 37% confirmed that I-MUR found problems
with their medications and 27% agreed that changes
were made to their medication after the I-MUR. Half the
patients would consider having another I-MUR and 85%
would recommend the service to other patients [24]. A
focus group was held which was attended by four GPs.
GPs’ views about I-MUR was positive. They identified
the potential for the I-MUR to improve patients’ adhe-
rence, quality of life, result in safer use of medicines and
better health care outcomes. GPs suggested developing
and sharing training sessions, underlining the fact that
GPs and pharmacists should work together, empowering
each other, and sending a consistent message to their pa-
tients [25].
In Italy no other work has been conducted on asthma
involving community pharmacists, therefore this current
study is needed to determine whether the I-MUR can
contribute to improve asthma outcomes and to demon-
strate whether the service provides clinical and cost ben-
efits, as these were not included in pilot work. The study
will provide evidence about the practicability and costs
of provision and the effectiveness of the I-MUR in asth-
matic patients.
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What are the principal research questions to be
addressed?
Is the I-MUR service provided by community pharma-
cists in Italy effective in:
I. Reducing the severity of asthma as assessed by the
Asthma Control Test (ACT) score?
II. Optimising the number of medicines (active
ingredients) used by patients?
III. Identifying and resolving pharmaceutical care
issues?
IV. Improving patients’ adherence to asthma
medications?
V. Reducing costs (direct and indirect) related to the
reduction of the severity of asthma?
Risks and safety issues
During this study there will be no risks for patients.
Those patients receiving the I-MUR service will be at no
greater risk than those receiving usual clinical care.
Pharmacists will ask their patient to complete the ACT
tool and will provide the I-MUR service. They will not
dispense or administer any medications based on the
results of the ACT or I-MUR results. Pharmacists will
neither be involved in the interpretation of diagnostic
tests, nor their results.
The activity involved in this study will not expose
pharmacists to any risk beyond their normal professional
practice.
Study design
This will be a clustered randomised controlled trial with
multiple data collection points.
Data will be collected from 360 Italian pharmacists
who will provide I-MUR services to 1800 patients over a
nine-month period.
A standard randomised study design would mean that
some pharmacists would not provide the I-MUR service
to their patients, in order to form a control group, an
approach which could lead to demoralise and disengage
pharmacists who will not have the chance to provide the
service. In addition, individual pharmacists may differ in
their practices, and their patients may be cared for by
GPs with different practices. Hence the study design
must minimise the impact of any individual pharmacist
or GP on the management of asthma. To avoid these
problems, it was decided to design a cluster randomised
control trial in which pharmacists are randomly allo-
cated to provide the intervention to their patients either
early or later during the study period. Randomisation
will be at pharmacist level, not at patient level, with each
pharmacist representing a cluster and outcome being
measured for individuals within those clusters [26].Data will be collected before, during and after inter-
vention delivery, to assess if timing of the intervention
affects the primary outcome: the severity of asthma.
Study setting
Italy is a country with nearly sixty million people and it
is divided in 20 regions. Pharmacist participants will be
selected from different regions throughout the country
to reduce potential impact from North–South climatic
variation, which could impact asthma severity. Selected
regions include Trentino Alto Adige, Lombardia, Sicilia,
Puglia, Sardegna, Piemonte, Valle d’Aosta, Veneto, Friuli
Venezia Giulia, Toscana, Emilia Romagna, Marche,
Abruzzo, Lazio and Campania. Pharmacists will be
stratified by region before randomisation. These geo-
graphical areas were identified and selected by the Italian
Pharmacists’ Federation following attendance at regional
presentations of the study conducted by the principal in-
vestigator (PI).
What is the aim and what are the planned trial
interventions?
Aim
To evaluate the outcomes of I-MUR interventions pro-
vided by Italian community pharmacists in an asthmatic
patient population.
Planned intervention
Pharmacists will provide the I-MUR service following
administration of the ACT at either T0 or T3 depending
on group allocation, recording details of all PCIs identi-
fied and advice provided during the I-MUR consultation.
The I-MUR intervention covers the following areas:
patients’ demographics, their regular medications (active
ingredients) including those used for asthma, patients’
attitude towards their medications and adherence to
treatments assessed with the I-MUR interview, pharma-
ceutical care issues identified by the pharmacist, phar-
macist’s advice given to patients, including healthy living
advice, pharmacist’s advice given to Doctors, pharma-
cist’s own view on the potential benefit to the patient of
the MUR service they provided.
Following each consultation, pharmacists will be re-
quired to enter the results into the web-based template
provided, maintaining patient anonymity.
Sample selection
Pharmacists
Who wrote to the pharmacists? An invitation letter
and a summary of the study was prepared by the PI and
sent to FOFI.
FOFI distributed the above information to all commu-
nity pharmacists in all the identified regions inviting
pharmacists to participate in the study.
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pressed interest in participating were invited to attend a
regional presentation. At the regional presentations, which
took place between March and April 2014, the PI outlined
the study protocol and the enrollment criteria and partici-
pants were given a detailed participant information sheet.
The regional team leader collated names of pharma-
cists who expressed interest over the next three to four
weeks and the first 36 who met the inclusion criteria
(see below) were selected for study inclusion and invited
to the I-MUR training.
Pharmacist inclusion and exclusion criteria
Pharmacies must have
 a private area for private consultation with patients;
 an internet connection available where the
consultation will take place.
Pharmacists must
 be qualified and registered with the Italian Pharmacy
Board practising in Italy;
 have at least one year of experience in providing
advice to patients;
 already provide one or more services such as blood
pressure monitoring, smoking cessation, cholesterol
monitoring, signposting, food intolerance testing., in
order to demonstrate advanced consultation skills
and experience;
 be able to attend training sessions.
Pharmacies must be excluded if they
 have no internet access; or
 no consultation room.
 are currently involved in any other clinical
pharmacy research project.
Patient selection
Patient inclusion and exclusion criteria
Patients will be identified by the individual pharmacists
from their medication history, from their prescriptions,
or by referral from GP, according to inclusion and exclu-
sion criteria listed below.
Patients must:
 be at least 18 years of age;
 have been diagnosed with asthma, for at least six
months before enrolment to the study;
 have a prescription(s) for asthma medication with
R03 as ATC code (Anatomical, Therapeutic
Chemical Classification), or drugs for obstructive
airways disease.Patients must be excluded if they
 have terminal illness (defined as an advanced stage
of a disease with an unfavourable prognosis and no
known cure) as identified by the pharmacists
through the prescription coding;
 are currently enrolled in another clinical trial;
 do not self-administer their inhaler;
 are not able to communicate well in Italian both
written and spoken.
Recruitment and informed consent
Pharmacists, after having assessed patients’ eligibility for
the study, will provide an information letter and consent
form to each patient, who will be given an opportunity
to consider their participation. All signed consent forms
will be retained by the pharmacist in the pharmacy.
Procedures
Pharmacist randomisation and blinding
An academic member of staff at Medway School of Phar-
macy, experienced in clinical trials will be in charge of the
randomisation process. Pharmacists will be randomly allo-
cated to group A or B. Pharmacists will be stratified by lo-
cation, prior to randomisation, using computer-generated
random numbers. Blinding will not be possible either at
pharmacist or patient level because the nature of the inter-
vention requires their full knowledge. However the PI, as
assessor of the main outcome measure, severity of asthma,
will remain blind throughout. As group allocation will be
intrinsic to the data gathered for each patient, in order to
maintain blindness, the PI will access the data only after
all patients have been followed up at three months (see
Figure 1).
Pharmacist training
Training sessions will last for a half day and will be pro-
vided in each region by the PI, a fully trained and quali-
fied pharmacist accredited to provide MURs in England
since 2005. The training supports the development of
pharmacists’ clinical skills and knowledge using question
and answer sessions, mock interviews and role-play. The
training material was developed and evaluated during
earlier work. Contributions to the training will also be
included from local respiratory consultants and general
practitioners who will cover asthma management, phy-
siopathology, medical conditions, different treatments
according to asthma severity and GINA guidelines.
Pharmacists from Groups A and B will be trained at dif-
ferent times. The use of the ACT test will be explained
to both groups before T0 but only group A will receive
the I-MUR training at this time point; group B will re-
ceive this training just before T3.
Figure 1 Flow diagram for the study (Adapted from BMJ 2012; 345:e5661 doi:10.1136/Bmj.e5661, September 2012).
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The planned duration of the study is nine months.
ACT
The ACT (primary outcome measure) is a patient-
completed questionnaire with five items assessing asthma
symptoms (daytime and nocturnal), use of rescue medica-
tions, and the effect of asthma on daily functioning. Each
item includes response options corresponding to a 5-point
Likert scale, which are summed to yield a score ranging
from 5 (poor asthma control) to 25 (complete asthma
control). Schatz et al. [27] found that a cut off score of 19
or less identifies patients with poorly controlled asthma.
How will the ACT test be administered?
Pharmacists will administer ACT tests to their patients in
the pharmacy consultation area allowing patients’ privacy
to read the questions and take the necessary time to
respond.
I-MUR
This will take place in the pharmacy private consultation
area. The estimated time for the consultation will be
26 minutes based on phase one experience.
Data collection
Data collected during the I-MUR will include patient
demographics, their regular medications (active ingre-
dients) including those used for asthma, patients’ attitude
towards their medications and adherence to treatmentsassessed during the I-MUR interview, PCIs identified by
the pharmacist, pharmacist’s advice given to patients, in-
cluding healthy living advice, pharmacist’s advice given to
doctors, pharmacist’s own view on the potential benefit to
the patient of the MUR service they provided.
Following each consultation, pharmacists will be re-
quired to enter the data from each consultation into the
web-based template provided, maintaining patient ano-
nymity. This process was developed and tested during
earlier work [21].
Data collected at multiple time points will be patients’
responses to ACT, adherence to asthma treatment and
number of active ingredients (see Figure 2).
Proposed sample size
It is aimed to obtain a final sample size of 360 pharma-
cists and 1800 patients, requiring each pharmacist to
provide the intervention to five patients. The power cal-
culation for this study has been conducted taking into
consideration the intra-cluster and inter-cluster corre-
lation (ICC) using SPSS sample power calculation. The
ICC represents the correlation between responses of in-
dividuals in the same clusters which is a proportion of
the total variation explained by variation between clus-
ters [28] and its value ranges between 0 and 1. For this
study it was decided to use an ICC = 0.02 as this was
used in a similar study conducted in Australia [17]. This
is based on an estimated 20% difference in asthma
severity (ACT score), which may be achieved, again
based on the Australian study [17], which found that the
Figure 2 Study timeline, showing activities provided by pharmacists and information gathered.
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declined from 87.9% to 52.7% following pharmacist
intervention. This is based on an anticipated 40% im-
provement in asthma severity following pharmacist
intervention; the difference will be measured by compa-
ring the ACT score gathered at baseline to T3, T6, T9
for each patient, where an ACT score ≤ 19 means not
well controlled asthma and an ACT score ≥ 20 well con-
trolled asthma.
Four options were considered (Table 1) all using d = 20%
and alpha = 0.05, but considering different numbers of
pharmacists and patients per pharmacy. Option d was
chosen, as it has a power of 95%. The calculated ratio bet-
ween pharmacists and patient in order to achieve the
above results is 1:4. The attrition rate was estimated as
23% based on the Australian study, which had an attrition
rate of 14%, but following which the authors suggested
that this percentage could be in the range of 14-25% [17].
Therefore pharmacists will be required to recruit five pa-
tients instead of four. Based on an attrition rate of 23%,
396 patients will not complete the study, leaving 1386,
which is still sufficient to attain option d (693 patients per
group).
Data analysis
In studies where the important baseline factors seem
well balanced, it is likely that any differences in outcomeTable 1 Elements for the evaluation of the power analysis
Options Power level ICC d Alph
A 90% 0.02 20% 0.05
B 90% 0.02 20% 0.05
C 95% 0.02 20% 0.05
D 95% 0.02 20% 0.05between intervention and control groups are a real effect
of treatment, which is one component of the internal
validity. Patients’ location, age, gender and ACT score
will be collected and compared at baseline. This baseline
ACT score will provide information regarding the level/
severity of asthma prior to intervention delivery.
Quantitative data gathered through the web platform
(Qualtrics©) will be exported and analysed using SPSS
version 22. Patient location, age, gender and ACT score
will be compared at baseline.
Asthma severity assessed by ACT score will be ana-
lysed over time within individual patients to obtain a
percentage change score. Scores will be compared bet-
ween groups at all times points. The number of active
ingredients in use and reported adherence to treatment
will be compared at three time points after provision of
the I-MUR. The number of PCIs identified and advice
given by pharmacists will be captured for both groups
separately and combined. Any change in the severity of
asthma and the accompanying percentage variation in
cost (based on peer reviewed published data) will also be
assessed. It will be possible to compare data before and
after the I-MUR intervention for group A and B, sepa-
rately and combined. In addition findings will be ana-
lysed by region.
A significance level (alpha) of 0.05 will be used in all
analyses. Between-group differences at baseline will bea Number of
pharmacists
per group
Number of
patients per
group
Pharmacists
patients ratio
115 575 1:5
140 560 1:4
140 700 1:5
173 693 1:4
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nuous parameters and Pearson’s χ2 will be used for cate-
gorical parameters. Outcomes for continuous parameters
will be evaluated using repeated measures multivariate
ANOVA.
The analysis will be conducted in two steps. Step one
will represent an interim analysis after the first six
months, after completion of T6, by which time all pa-
tients will have been followed up for three months after
the intervention. Step two will represent the final ana-
lysis, which will be conducted at the end of the study
after T9.
Primary outcome measure
Primary outcome
 Severity of asthma: before, during and after the
I-MUR service provision assessed using the
ACT score.
Secondary outcomes
 Number of active ingredients used by patients
during and after the I-MUR service provision,
as reported by patients.
 Number of PCIs identified during the I-MUR service
provision, classified using the method of Krska et al.
 Patients’ adherence to asthma medication during
and after the I-MUR service provision, measured
using questions embedded within the I-MUR
instrument.
 Cost estimated on the severity of asthma, before,
during and after the I-MUR service provision.
Discussion
This study has been developed because of the need for a
new way of working for pharmacists and pharmacy in
Italy. If the results are positive, the study has the poten-
tial to open up a new professional perspective for Italian
community pharmacists, providing this is accepted by all
stakeholders: Italian medicine control agency (AIFA =
Agenzia Italiana del Farmaco), Italian Ministry of Health,
Italian general practitioners and hospital doctors.
It is also important internationally, as it is one of the
largest studies ever conducted in community pharmacy
and the first and largest study ever conducted in Italy,
involving 75% of Italian regions.
Conclusion
This is the first trial of any community pharmacy-based
pharmaceutical care intervention to be carried out in
Italy. The results of this study will inform future policy
and practice in Italian community pharmacy.Strengths and limitations
This is the first study conducted in Italy aiming to assess
pharmacists’ contribution to reducing the severity of
asthma; it is one of the largest studies conducted in one
single country and it introduces a new systematic and
quantitative research instrument: I-MUR.
The study includes only adults, does not require spiro-
metric testing and will run for nine months. We do antici-
pate, given the size of the study, that problems may arise,
for example, with pharmacist and patient recruitment,
resulting in the study being underpowered. However we
have taken account of this in our power calculation, by
evaluating four possible options based on actual results
from phase one. There is also the possibility of a higher
drop-out rate than anticipated and, while the study will
enable us to assess whether ACT score is a suitable pri-
mary outcome measure, this may prove not to be the case.
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